



Attorney's Docket No.: 00786-071005

GAU1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gino V. Segre et al. Art Unit : 1646  
Serial No. : 09/199,874 Examiner : M. Pak  
Filed : November 24, 1998  
Title : PARATHYROID HORMONE RECEPTOR AND DNA ENCODING SAME

B/13  
7/10/02

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES

In response to the action mailed June 20, 2000, please consider the following amendments and remarks.

In the Specification:

At page 8, line 2, insert --(SEQ ID NO:1)-- after "nucleic acid".  
At page 8, line 3, insert --(SEQ ID NO:18)-- after "amino acid".  
At page 8, line 4, delete "(SEQ ID NO.: 1)".  
At page 8, line 5, insert --(SEQ ID NO:2)-- after "nucleic acid".  
At page 8, line 6, insert --(SEQ ID NO:19)-- after "amino acid".  
At page 8, line 7, delete "(SEQ ID NO.: 2)".  
At page 8, line 8, insert --(SEQ ID NO:3)-- after "nucleic acid".  
At page 8, line 9, insert --(SEQ ID NO:20)-- after "amino acid".  
At page 8, line 10, delete "(SEQ ID NO.: 3)".  
At page 8, line 12, insert --(SEQ ID NO:19)-- after "OK-O".  
At page 8, line 12, insert --(SEQ ID NO:20)-- after "R15B".  
At page 8, line 14, insert --(SEQ ID NO:19)-- after "OK-O".

RECEIVED  
JUL 06 2002  
TECH CENTER 1600/290A

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

June 30, 2000  
\_\_\_\_\_  
Date of Deposit  
Jeanine Mecherkany  
\_\_\_\_\_  
Signature  
Jeanine Mecherkany  
\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

At page 8, line 14, insert --(SEQ ID NO:18)-- after "OK-H".  
At page 8, line 14, insert --(SEQ ID NO:20)-- after "R15B".  
At page 8, line 16, insert --(SEQ ID NO:4)-- after "nucleic acid".  
At page 8, line 17, insert --(SEQ ID NO:21)-- after "amino acid".  
At page 8, line 18, delete "(SEQ ID NO.: 4)".  
At page 10, line 7, insert --(SEQ ID NO:20)-- after "R15B".

In the Claims:

25. (Amended) The polypeptide of claim 24, wherein said fragment is

- TNETREREVFDRLLGMIYTVG (SEQ ID NO:5),
- YLYSGFTLDEAERLTEEEL (SEQ ID NO:6),
- VTFFLYFLATNYYWILVEG (SEQ ID NO:7),
- Y-RATLANTGCWDLSSGHKKWIQVP (SEQ ID NO:8),
- PYTEYSGTLWQIQMHYEM (SEQ ID NO:9),
- DDVFTKEEQIFLTHRAQA (SEQ ID NO:10),
- FFRLHCTRNY (SEQ ID NO:11),
- EKKYLWGFTL (SEQ ID NO:12),
- VLATKLRETNAGRCCTRQQYRKLLK (SEQ ID NO:13), or
- a fragment or analog of (a) - (i) which is capable of binding parathyroid hormone or parathyroid hormone-related protein.

REMARKS

The specification and the claims have been amended in accordance with 37 C.F.R. §§ 1.821 through 1.825. No new matter has been added by the above amendments. In regard to the paper and computer readable forms of the sequence listing, applicants note that both forms fully complying with 37 C.F.R. §§ 1.821 through 1.825 was originally submitted on February 23, 2000, then resubmitted on April 4, 2000 because the sequence listing for this case was misplaced by the PTO. Thus, it is applicants' understanding that the application is now in full compliance with the sequence listing rules, without a third submission of a paper and computer readable form of the sequence listing.

Applicant : Gino V. Segre et al.  
Serial No. : 09/199,874  
Filed : November 24, 1998  
Page : 3

Attorney's Docket No.: 00786-071005

Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,


Date: 6-28-00

John T. Li

John T. Li  
Reg. No. 44,210

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20074518.doc



Application No.: 09/199,874

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: Claim 25 lists sequences without a sequence identifier. Figures 1-5 contain sequences which is not identified in the Brief description of drawings by a sequence identifier.

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**